Research at Radial

Backed by research.
Driven by care.

Radial clinicians don't just follow the research, they conduct it. From neuromodulation to digital psychiatry, our team actively publishes and participates in clinical trials, ensuring every patient receives care that is grounded in the best available evidence.

Featured publication

Mentalization-Based Treatment for Adolescents: The Framework for Work with Suicide and Self-Injurious Behaviors

Adolescents who self-harm or experience suicidal ideation are among the most challenging patients to engage therapeutically. This chapter presents the Mentalizing-Based Treatment framework for navigating these high-stakes clinical situations with structure, safety, and relational attunement.

View
Trudie Rossouw, Owen Muir, Laurel L Williams
Adolescents who self-harm or experience suicidal ideation are among the most challenging patients to engage therapeutically. This chapter presents the Mentalizing-Based Treatment framework for navigating these high-stakes clinical situations with structure, safety, and relational attunement.
Recently in research
Clinical Trials
June 2026

Cross-Dataset Evaluation of an Automated Video-Based Model for Detecting Tardive Dyskinesia Using the Clinician's Tardive Inventory: Validation Study

Trosch R, Sterns A, Grimm B, Larsen L, Talbot B, Ma F, Ranjan R, MacMillan C, Hughes J, Friedman J, Muir O
Can AI reliably spot a movement disorder that clinicians routinely miss? This validation study found that an AI-powered video analysis model accurately detected tardive dyskinesia — a common side effect of long-term antipsychotic use — even when video recordings weren't collected under standardized conditions. The model showed strong agreement with expert clinician ratings and high diagnostic accuracy, suggesting it could support earlier, more consistent screening in real-world clinical settings.
External Publications
April 2026

Mentalization-Based Treatment for Adolescents: The Framework for Work with Suicide and Self-Injurious Behaviors

Trudie Rossouw, Owen Muir, Laurel L Williams
Adolescents who self-harm or experience suicidal ideation are among the most challenging patients to engage therapeutically. This chapter presents the Mentalizing-Based Treatment framework for navigating these high-stakes clinical situations with structure, safety, and relational attunement.
External Publications
April 2026

Real-world efficacy of deep TMS for obsessive-compulsive disorder: interim post-marketing analysis of 192 patients from twenty-two sites

Geoffrey Grammer, Aron Tendler, Mehmet Kemal Arikan, Ryan Vidrine, David Kent, Owen Muir, Carlene MacMillan, Leah Casuto, William Sauve, Kellie Tolin, Steven A Harvey, Misty Borst, Robert Rifkin, Manish Sheth, Brandon Cornejo, Raul Rodriguez, Saad Shakir, Taylor Porter, Deborah Kim, Brent Peterson, Julia Swofford, Brendan Roe, Rebecca Sinclair, Tal Harmelech, Abraham Zangen, Yiftach Roth
Real-world OCD treatment rarely looks like a controlled trial — so what does Deep TMS actually deliver in practice? This interim post-marketing analysis across 22 sites offers some of the earliest real-world efficacy data for dTMS in obsessive-compulsive disorder.

Publications

April 2026
AI / Digital Psychiatry
Remote monitoring and AI for detecting tardive dyskinesia and improving patient outcomes.
A Sterns, L Larsen, B Grimm, OS Muir
Tardive dyskinesia disrupts lives — and often goes unrecognized until it's advanced. This study examines how remote AI monitoring can detect movement abnormalities earlier, enabling timely clinical response and better long-term patient outcomes.
No items found.
AI / Digital Psychiatry
April 2026
Deep TMS
Deep TMS H1 Coil treatment for depression: Results from a large post marketing data analysis
Aron Tendler, Stephan Goerigk, Samuel Zibman, Salomé Ouaknine, Tal Harmelech, Gaby S Pell, Abraham Zangen, Steven A. Harvey, Geoffrey Grammer, Jimmy Stehberg, Oluremi Adefolarin, Owen Muir, Carlene MacMillan, Diana Ghelber, Walter Duffy, Irakli Mania, Zeeshan Faruqui, Faisal Munasifi, Todd Antin, Frank Padberg, Yiftach Roth
What happens when you look at Deep TMS outcomes across more than a thousand patients in real clinical practice? This large post-marketing analysis confirms high response and remission rates for the H1 coil in community settings, with durable effects.
No items found.
Deep TMS
April 2026
Deep TMS
Real world efficacy and safety of various accelerated deep TMS protocols for major depression
Yiftach Roth, Colleen A Hanlon, Gaby Pell, Samuel Zibman, Tal Harmelech, Owen S Muir, Carlene MacMillan, Tim Prestley, David C Purselle, Thomas Knightly, Aron Tendler
Not all accelerated Deep TMS protocols are created equal — so which works best? This Phase IV analysis compared multiple accelerated dosing schedules in real-world MDD patients, finding strong and comparable efficacy across 2, 3, 5, and 10 sessions per day.
No items found.
Deep TMS
April 2026
Ketamine Monitoring
Evaluating passive physiological data collection during Spravato treatment
Todd M Solomon, Matus Hajduk, Martin Majernik, Jamileh Jemison, Alexander Deschamps, Jenna Scoggins, Adam Kolar, Miguel Amável Pinheiro, Peter Dubec, Ondrej Skala, Owen Muir, Amanda Tinkelman, Daniel R Karlin, Robert Barrow
Spravato sessions generate rich physiological data — but is anyone capturing it? This study evaluates passive data collection during esketamine treatment, exploring whether wearable monitoring can yield clinically meaningful insights without disrupting care.
No items found.
Ketamine Monitoring
April 2026
Psychedelic Therapy
Psychedelic Therapy: A Primer for Primary Care Clinicians—The Strengths, Weaknesses, Opportunities, and Threats of Psychedelic Therapeutics
Owen S Muir, Kenneth Shinozuka, Bryce D Beutler, Alejandro Arenas, Kirsten Cherian, Viviana D Evans, Chelsey Fasano, Burton J Tabaac
Psychedelic therapy isn't just about individual compounds — it requires a framework for evaluating the whole field. This paper maps the strengths, weaknesses, opportunities, and threats facing psychedelic therapeutics as they move toward mainstream medicine.
No items found.
Psychedelic Therapy
April 2026
Psychedelic Therapy
Psychedelic Therapy: A Primer for Primary Care Clinicians—Ibogaine
Kirsten Cherian, Kenneth Shinozuka, Burton J Tabaac, Alejandro Arenas, Bryce D Beutler, Viviana D Evans, Chelsey Fasano, Owen S Muir
Ibogaine carries both remarkable therapeutic promise and significant safety considerations. This primer helps primary care clinicians understand the evidence, risks, and clinical context for this powerful plant-derived compound.
No items found.
Psychedelic Therapy
April 2026
Psychedelic Therapy
Psychedelic Therapy: A Primer for Primary Care Clinicians—N, N-Dimethyltryptamine and Ayahuasca
Kenneth Shinozuka, Burton J Tabaac, Alejandro Arenas, Bryce D Beutler, Kirsten Cherian, Viviana D Evans, Chelsey Fasano, Owen S Muir
DMT is among the least understood psychedelics entering therapeutic research — and patient questions are outpacing clinical preparation. This primer offers primary care providers a practical evidence review for informed conversations.
No items found.
Psychedelic Therapy
April 2026
Psychedelic Therapy
Psychedelic Therapy: A Primer for Primary Care Clinicians—Lysergic Acid Diethylamide (LSD)
Bryce D Beutler, Kenneth Shinozuka, Burton J Tabaac, Alejandro Arenas, Kirsten Cherian, Viviana D Evans, Chelsey Fasano, Owen S Muir
LSD has re-entered serious clinical research after decades of prohibition. This primer gives primary care clinicians a grounded overview of current evidence, safety data, and therapeutic applications of lysergic acid diethylamide.
No items found.
Psychedelic Therapy
April 2026
Psychedelic Therapy
Psychedelic therapy: a primer for primary care clinicians—ketamine
Viviana D Evans, Alejandro Arenas, Kenneth Shinozuka, Burton J Tabaac, Bryce D Beutler, Kirsten Cherian, Chelsey Fasano, Owen S Muir
Ketamine is already in primary care — but many clinicians lack a framework for its psychiatric applications. This primer covers mechanism, dosing, evidence, and patient selection, helping frontline providers engage knowledgeably with patients seeking this treatment.
No items found.
Psychedelic Therapy
April 2026
Psychedelic Therapy
Psychedelic Therapy: A Primer for Primary Care Clinicians—Historical Perspective and Overview
Burton J Tabaac, Kenneth Shinozuka, Alejandro Arenas, Bryce D Beutler, Kirsten Cherian, Viviana D Evans, Chelsey Fasano, Owen S Muir
Psychedelic therapy didn't begin in research labs — it has a long, complex history worth understanding. This primer traces the historical foundations of psychedelic medicine, providing primary care clinicians with context for the current therapeutic renaissance.
No items found.
Psychedelic Therapy
No items found.
No items found.
Personality Disorders
Narcissism
No items found.
No items found.
Mentalizing-Based Therapy
No items found.
Deep TMS
No items found.
Deep TMS
No items found.
Mentalizing-Based Therapy
No items found.
Mentalizing-Based Therapy
No items found.
Deep TMS
No items found.
AI / Digital Psychiatry
No items found.
No items found.
No items found.
Deep TMS
No items found.
Deep TMS
No items found.
Deep TMS
No items found.
Ketamine Monitoring
Movement Disorders
AI / Digital Psychiatry
No items found.
Accelerated TMS
No items found.
AI / Digital Psychiatry
No items found.
Accelerated TMS
No items found.
No items found.
No items found.
Accelerated TMS
No items found.
TMS
No items found.
Psychedelic Therapy
No items found.
Psychedelic Therapy
No items found.
Psychedelic Therapy
No items found.
Psychedelic Therapy
No items found.
Psychedelic Therapy
No items found.
Psychedelic Therapy
No items found.
Psychedelic Therapy
No items found.
Psychedelic Therapy
No items found.
Deep TMS
No items found.
Mentalizing-Based Therapy
No items found.
Accelerated TMS
No items found.
Accelerated TMS
No items found.
Accelerated TMS
No items found.
No items found.
No items found.
Deep TMS
No items found.
Deep TMS
No items found.
No items found.
No items found.
Deep TMS
No items found.
Accelerated TMS
No items found.
Ketamine Therapy
Filter Publications
Conditions
Treatments
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Active Clinical Trials

AI / Digital Psychiatry

Cross-Dataset Evaluation of an Automated Video-Based Model for Detecting Tardive Dyskinesia Using the Clinician's Tardive Inventory: Validation Study

Can AI reliably spot a movement disorder that clinicians routinely miss? This validation study found that an AI-powered video analysis model accurately detected tardive dyskinesia — a common side effect of long-term antipsychotic use — even when video recordings weren't collected under standardized conditions. The model showed strong agreement with expert clinician ratings and high diagnostic accuracy, suggesting it could support earlier, more consistent screening in real-world clinical settings.
View
Trosch R, Sterns A, Grimm B, Larsen L, Talbot B, Ma F, Ranjan R, MacMillan C, Hughes J, Friedman J, Muir O
Can AI reliably spot a movement disorder that clinicians routinely miss? This validation study found that an AI-powered video analysis model accurately detected tardive dyskinesia — a common side effect of long-term antipsychotic use — even when video recordings weren't collected under standardized conditions. The model showed strong agreement with expert clinician ratings and high diagnostic accuracy, suggesting it could support earlier, more consistent screening in real-world clinical settings.

Recent PR

Press

Postpartum OCD: Why New Parents Experience Frightening Intrusive Thoughts

Postpartum OCD can cause terrifying intrusive thoughts, compulsive checking, and intense fear after childbirth. Learn what's happening and how to get help.
View more

Leadership

Dr. Owen Scott Muir

Co-founder & Chief Medical Officer

MD, DFAACAP

Dual board-certified child, adolescent and adult psychiatrist, and author of the award-winning Frontier Psychiatrists newsletter and podcast

Read more

Dr. Carlene MacMillan

Co-founder & Chief Product Officer

MD, FCTMSS, DFAACAP

Dual board-certified child, adolescent, and adult psychiatrist focused on expanding access to breakthrough treatments through better technology and insurance coverage advocacy.

Read more

John Capecelatro

CEO & Co-Founder

Elliot Cohen

Executive Chairman & Co-Founder

Stephanie Fillion

VP of Engineering

Jonathan Murray

Chief Commercial Officer

Leah Connor

VP of Operations

Take the first step and talk to a care navigator.

Your care navigator will explain the process, discuss insurance and costs, and connect you with a clinician to explore today’s most advanced mental health treatments.

Get started
Radial logo
Treatments
dropdown arrow
Locations
dropdown arrow
About Radial
dropdown arrow
Legal
dropdown arrow
New & Existing Patients
dropdown arrow
Business Inquiry
dropdown arrow